Hereditary Angioedema Therapeutics Market Report 2026

Hereditary Angioedema Therapeutics Market Overview

• Hereditary Angioedema Therapeutics market size has reached to $7.77 billion in 2025 • Expected to grow to $19.03 billion in 2030 at a compound annual growth rate (CAGR) of 19.7% • Growth Driver: Growth Of The Hereditary Angioedema Therapeutics Market Driven By Increasing Healthcare Expenditure • Market Trend: Innovative Oral Treatments Transforming Management of Hereditary Angioedema • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hereditary Angioedema Therapeutics Market?

Hereditary angioedema (HAE) therapeutics refers to therapy for an autosomal dominant condition brought on by a deficiency in or malfunction of the C1-inhibitor protein. Hereditary angioedema symptoms include angioedema-related upper airway, cutaneous, and, or gastrointestinal complaints. The main drug classes of hereditary angioedema therapeutics are C1 esterase inhibitor, selective bradykinin B2 receptor antagonist, kallikrein inhibitor, others. C1 Esterase Inhibitor refers to a protein called that is present in the fluid portion of blood and it regulates the complement system's protein C1, which goes by the name of C1. The therapeutics are administered through intravenous, subcutaneous, and oral, distributed via hospital pharmacy, retail pharmacy, and others. The application of hereditary angioedema therapeutics include prophylaxis and on-demand.

What Is The Hereditary Angioedema Therapeutics Market Growth Forecast?

The hereditary angioedema therapeutics market size is expected to see rapid growth in the next few years. It will grow to $19.03 billion in 2030 at a compound annual growth rate (CAGR) of 19.7%. The growth in the forecast period can be attributed to growth in recombinant c1 esterase inhibitors, adoption of subcutaneous delivery methods, rising prophylactic therapy usage, expansion of specialty pharmacy channels, increasing investment in rare disease research. Major trends in the forecast period include personalized therapy development, increased orphan drug approvals, advancements in subcutaneous drug delivery, development of on-demand treatment options, expansion of hospital and retail pharmacy networks.

Global Hereditary Angioedema Therapeutics Market Segmentation

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes 2) By Route of Administration: Intravenous, Subcutaneous, Oral 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels 4) By Application: Prophylaxis, On-Demand

What Is The Driver Of The Hereditary Angioedema Therapeutics Market?

The increasing healthcare expenditure is expected to boost the growth of the hereditary angioedema therapeutics market going forward. Healthcare expenditure refers to the total amount of resources, including financial resources, spent on healthcare goods and services within a specific period in a given geographical area. Greater healthcare expenditure allows for increased investment in research and development activities focused on understanding the underlying causes of hereditary angioedema and developing innovative therapeutic solutions. For instance, in June 2025, according to the Centers for Medicare & Medicaid Services (CMS), the US-based federal agency, National Health Expenditure (NHE) grew 7.5% to $4.9 trillion in 2023, or $14,570 per person, and accounted for 17.6% of Gross Domestic Product (GDP). Hospital expenditures grew 10.4% to $1,519.7 billion in 2023, faster than the 3.2% growth in 2022. Therefore, the increasing healthcare expenditure is driving the growth of the hereditary angioedema therapeutics industry.

Key Players In The Global Hereditary Angioedema Therapeutics Market

Major companies operating in the hereditary angioedema therapeutics market are Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals (for pipeline HAE therapies), PharmAthene Inc., BioMarin Pharmaceutical Inc.

Global Hereditary Angioedema Therapeutics Market Trends and Insights

Major companies operating in the hereditary angioedema (HAE) therapeutics market are developing innovative treatments, such as oral plasma kallikrein inhibitors, to enhance patient management and provide effective, on-demand options for alleviating HAE attacks, thereby improving overall patient outcomes and quality of life. Oral plasma kallikrein inhibitors are drugs taken by mouth that inhibit the enzyme plasma kallikrein, helping to manage and reduce the severity of hereditary angioedema attacks. For instance, in September 2024, KalVista Pharmaceuticals, a US-based biopharmaceutical company, received US. Food and Drug Administration of New drug application for Sebetralstat, aiming to offer HAE patients a more convenient, non-invasive treatment alternative to intravenous or subcutaneous medications. This solution meets the growing demand for fast, effective oral treatments that can be administered immediately during an hereditary angioedema attack.

What Are Latest Mergers And Acquisitions In The Hereditary Angioedema Therapeutics Market?

In February 2023, Takeda Pharmaceutical Company, a Japan-based pharmaceutical company, acquired Nimbus Lakshmi Inc. from Nimbus Therapeutics LLC for an undisclosed amount. This acquisition strengthens Takeda's growing late-stage pipeline to expand its portfolio and patient impact across multiple indications and maintains strong global growth over the medium to long term. Nimbus Lakshmi, a fully-owned subsidiary of Nimbus Therapeutics, is a US-based company that provides Tyrosine kinase 2 (TYK2) inhibitor NDI-034858.

Regional Insights

North America was the largest region in the global hereditary angioedema therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hereditary Angioedema Therapeutics Market?

The hereditary angioedema therapeutics market includes revenues earned by entities by diagnosis and evaluation, treatment, and management of hereditary angioedema. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary angioedema therapeutics market also includes of sales of tranexamic acid, danazol, intravenous and subcutaneous nano-filtered purified plasma-derived human C1 esterase inhibitor concentrate, and lanadelumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hereditary Angioedema Therapeutics Market Report 2026?

The hereditary angioedema therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary angioedema therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.